binder

(redirected from Phosphate binder)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.

Binder

A written document that records the essential provisions of a contract of insurance and temporarily protects the insured until an insurance company has investigated the risks to be covered, or until a formal policy is issued.

A receipt for cash or for a check that is deposited by a prospective buyer with the seller to secure the right to purchase real estate at terms that have been agreed upon by both buyer and seller.

binder

n. a written statement of the key terms of an agreement, in particular insurance policies, so that the insured as well as lenders can be assured there is valid and adequate insurance coverage. (See: insurance)

binder

noun assurance, caution money, collateral, collateral security, deposit, earnest, escrow, expense outlay, gage, guaranty, handsel, indemnity, installment, investment, payment, pledge, receipt, receipt for payment, security, stake, token, token payment
Associated concepts: binder receipt, insurance binder, real essate binder
See also: connection
References in periodicals archive ?
1993) examined the use of a combination of calcium and magnesium carbonate as a phosphate binder in patients on continuous ambulatory peritoneal dialysis (CAPD) for a one-year period.
Studies that compare sevelamer and lanthanum with calcium-based phosphate binders demonstrate similar effectiveness at lowering serum phosphorus.
The oral powder formulation was developed by Shire to give patients more choice in how they take their phosphate binder.
Genzyme says Renvela is a next generation version of Renagel, a calcium-free, metal-free, non-absorbed phosphate binder, and has the added benefit of a carbonate buffer.
et al, The use of Renalzin, a new intestinal phosphate binder, in feline chronic renal failure.
While being severely restricted in fluid intake, CKD-5D patients take on average 10-14 oral medications each day, including 9 or more phosphate binder pills.
Zerenex (ferric citrate), a ferric iron-based phosphate binder, is currently in Phase 3 clinical development in the United States for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.
Lanthanum carbonate is indicated as a phosphate binder in patients with stage 5 chronic kidney disease (Anon, 2007).
Renvela is a next-generation version of the company's Renagel, the most-prescribed phosphate binder in the US.
Similar to the phosphate binder market, nephrologists reported initiating vitamin D at a mean iPTH level of 155pg/dL but the audited levels were significantly higher with 85 percent of patients initiated when iPTH levels exceeded 100pg/dL.
Auryxia is the first and only absorbable-iron-based phosphate binder that is clinically proven to effectively control phosphate levels within the KDOQI guidelines range of 3.